Drug discoverer Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) has teamed up with the Collaborative Trajectory Analysis Project to try and accelerate the development of its lead Duchenne muscular dystrophy candidate.
Summit’s utrophin modulator for the treatment of DMD – ezutromid – is currently in a phase II clinical trial, with data from the 48-week study expected in the third quarter of 2018.
But the dual-listed firm hopes that by partnering with cTAP, it can potentially adapt and improve the overall clinical process.
“In the Duchenne field, there is a strong community amongst the families, patient organisations, caregivers and industry that comes together to improve the lives of patients living with this disease, where time is of the essence,” said Dr David Roblin, President of R&D of Summit.
“cTAP is leveraging the natural history and clinical data collected within this community to create more predictive models of disease progression with the aim of enabling companies to interpret data and improve the design of clinical trials in DMD.
“We believe this could potentially benefit the development of our utrophin modulators for the treatment of all patients with DMD.”
Roblin added that Summit would also be able to contribute its own data to the project.
In late afternoon trading, Summit shares were up 1.3%, or 2.5p at 197.5p.
-- Updates share price --